Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | ESRRA | P11474 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.48 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8632740 | 0.90 | ESRRA (0.61) | ALDH1A1HSD17B10ALOX15NR1I2LMNA | |
| SCHEMBL2815926 | 0.86 | GAA (0.58) | ALDH1A1HSD17B10ALOX15NR1I2LMNA | |
| SCHEMBL9150850 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HSD17B10ALOX15NR1I2LMNA | |
| SCHEMBL9408554 | 0.84 | ALDH1A1 (0.78) | ALDH1A1HSD17B10ALOX15NR1I2LMNA | |
| SCHEMBL5953654 | 0.84 | MAPT (0.45) | ALDH1A1HSD17B10ALOX15LMNAGAA | |
| SCHEMBL9150596 | 0.84 | ALDH1A1 (0.45) | ALDH1A1HSD17B10ALOX15GAAL3MBTL1 | |
| SCHEMBL11799605 | 0.83 | ALDH1A1 (0.43) | ALDH1A1HSD17B10ALOX15LMNAHTT | |
| SCHEMBL7823292 | 0.82 | ALDH1A1 (0.53) | ALDH1A1HSD17B10ALOX15NR1I2LMNA | |
| SCHEMBL5634319 | 0.82 | NR5A1 (0.56) | ALDH1A1HSD17B10ALOX15NR1I2LMNA | |
| SCHEMBL11654654 | 0.82 | NR5A1 (0.56) | ALDH1A1HSD17B10ALOX15NR1I2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5399623-A | Semiconductors with sealing rubbers | DAIKIN INDUSTRIES, LTD. (JP) | 1995-03-21 | — | — | US | claimed |
| US-12559458-B2 | Co-crystals or salts of psilocin and methods of treatment therewith | Reset Pharmaceuticals, Inc. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4486448-A1 | CO-CRYSTALS OR SALTS COMPRISING PSILOCIN | Reset Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240383849-A1 | CO-CRYSTAL OR SALT | Reset Pharmaceuticals, Inc. | 2024-11-21 | — | — | US | disclosed |
| CN-118871423-A | Co-crystals or salts comprising xylometacin | 雷塞特制药股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12060328-B2 | Co-crystals or salts of psilocybin and methods of treatment therewith | Reset Pharmaceuticals, Inc. (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2023168023-A1 | CO-CRYSTALS OR SALTS COMPRISING PSILOCIN | Reset Pharmaceuticals, Inc. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168022-A1 | CO-CRYSTALS OR SALTS COMPRISING PSILOCYBIN | Reset Pharmaceuticals, Inc. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230279032-A1 | CO-CRYSTAL OR SALT | Reset Pharmaceuticals, Inc. | 2023-09-07 | — | — | US | disclosed |
| US-20230202978-A1 | CO-CRYSTAL OR SALT | Reset Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20080125531-A1 | Polymerizable Composition, Thermoplastic Resin Composition, Crosslinked Resin, And Crosslinked Resin Composite Materials | ZEON COROPRATION (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1589054-A1 | POLYMERIZABLE COMPOSITION, THERMOPLASTIC RESIN COMPOSITION, CROSSLINKED RESIN, AND CROSSLINKED RESIN COMPOSITE MATERIALS | Zeon Corporation (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-5849732-A | Phenol compound having antioxidative activity and the process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1998-12-15 | — | — | US | disclosed |
| EP-0790240-A1 | Phenol-derivatives having pharmaceutical activity and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
| US-5399623-A | Semiconductors with sealing rubbers | DAIKIN INDUSTRIES, LTD. (JP) | 1995-03-21 | — | — | US | disclosed |
| EP-0607457-A1 | VULCANIZING FLUORORUBBER COMPOSITION | DAIKIN INDUSTRIES, LTD. (JP) | 1994-07-27 | — | — | EP | disclosed |
| EP-0259303-B1 | FOG SUPPRESSANT FOR PHOTOTHERMOGRAPHIC IMAGING COMPOSITIONS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383849-A1 | CO-CRYSTAL OR SALT | SLC6A3, SLC6A2, OPRK1 | ALDH1A1 4473/4885HSD17B10 1877/4885ALOX15 3619/4885 |
| US-12060328-B2 | Co-crystals or salts of psilocybin and methods of treatment therewith | SLC6A3, SLC6A2, HTR2B | ALDH1A1 4504/4885HSD17B10 1938/4885ALOX15 3905/4885 |
| US-20230279032-A1 | CO-CRYSTAL OR SALT | SLC6A3, SLC6A2, OPRK1 | ALDH1A1 4473/4885HSD17B10 1877/4885ALOX15 3619/4885 |
| US-12559458-B2 | Co-crystals or salts of psilocin and methods of treatment therewith | SLC6A2, SLC6A4, SLC6A3 | ALDH1A1 2183/4885HSD17B10 1577/4885ALOX15 4082/4885 |
| US-20230202978-A1 | CO-CRYSTAL OR SALT | SLC6A3, SLC6A2, SLC6A4 | ALDH1A1 3987/4885HSD17B10 1857/4885ALOX15 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.